Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for PD-L1-high non-small-cell lung cancer without a driver mutation, drawn from the whole corpus: 29 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Half of PD-L1-high patients progress within a year and have no predictor to identify them in advance.
Whether adding chemotherapy to a checkpoint inhibitor prolongs survival in PD-L1-high disease has never been tested in a randomised trial.
The two-year stopping rule rests on trial design rather than evidence, and the safe minimum duration is unknown.
Ivonescimab's advantage over pembrolizumab has been shown only in China and only on progression-free survival so far.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 16 changes by month →When this page itself was last checked or edited.
Interim PFS not statistically significant (May 2026); final readouts pending.
PFS HR 0.
A milestone in how this cancer is treated.
PFS HR 0.
Median overall survival 14.